Current progress of anti‑PD‑1/PDL1 immunotherapy for glioblastoma (Review)
Molecular Medicine Reports · 30.09.2024 · 30 (6)
DOI: 10.3892/mmr.2024.13344 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Medicine Reports, online erschienen am 30.09.2024. Verfasst von Jianheng Wu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Gaozhou People's Hospital, Gaozhou, Guangdong 525200, P.R. China. Hauptthemen laut MEDLINE: Glioblastoma, Immunotherapy, B7-H1 Antigen, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Glioblastoma (GBM) is the most common central nervous system malignancy in adults. GBM may be classified as grade IV diffuse astrocytoma according to the 2021 World Health Organization revised classification of central nervous system tumors, which means it is the most aggressive, invasive, undifferentiated type of tumor. Immune checkpoint blockade (ICB), particularly anti‑programmed cell death protein‑1 (PD‑1)/PD‑1 ligand‑1 immunotherapy, has been confirmed to be successful across several tumor types. However, in GBM, this treatment is still uncommon and the efficacy is unpredictable, and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Gaozhou People's Hospital, Gaozhou, Guangdong 525200, P.R. China.
- Department of Gastroenterology, Gaozhou People's Hospital, Gaozhou, Guangdong 525200, P.R. China.
Zitieren
APA
Wu, J., & Wang, N. (2024). Current progress of anti‑PD‑1/PDL1 immunotherapy for glioblastoma (Review). Molecular Medicine Reports, 30(6). https://doi.org/10.3892/mmr.2024.13344
Vancouver
Wu J, Wang N. Current progress of anti‑PD‑1/PDL1 immunotherapy for glioblastoma (Review). Molecular Medicine Reports. 2024;30(6). doi:10.3892/mmr.2024.13344
BibTeX
@article{Wu2024,
author = {Wu, Jianheng and Wang, Nannan},
title = {Current progress of anti‑PD‑1/PDL1 immunotherapy for glioblastoma (Review)},
journal = {Molecular Medicine Reports},
year = {2024},
volume = {30},
number = {6},
doi = {10.3892/mmr.2024.13344}
}
EUVIMED